TCM
CRDL

Tradewinds Capital Management’s Cardiol Therapeutics CRDL Stock Holding History

Tradewinds Capital Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-500
Closed -$255 – 515
2022
Q4 		$255 Hold
500
– – ﹤0.01% 465
2022
Q3 		$1K Hold
500
– – ﹤0.01% 362
2022
Q2 		$1K Hold
500
– – ﹤0.01% 378
2022
Q1 		$1K Hold
500
– – ﹤0.01% 714
2021
Q4 		$1K Hold
500
– – ﹤0.01% 719
2021
Q3 		$2K Buy
+500
New +$1.81K ﹤0.01% 643

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AI
AXS Investments Port Chester, New York $248M AUM 15.95% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Tradewinds Capital Management's CRDL Position: Q1 2023 in Review

Tradewinds Capital Management sold out of Cardiol Therapeutics (CRDL) in Q1 2023, closing a stake of 500 shares — an estimated $255 sold.

Tradewinds Capital Management first reported a position in CRDL in Q3 2021 and held it in 6 quarters. The position peaked at $2K in Q3 2021. 35 funds tracked by Wall St. Rank hold CRDL as of Q1 2023.

  • Tradewinds Capital Management reported no remaining Cardiol Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Tradewinds Capital Management sold 500 Cardiol Therapeutics shares in Q1 2023, an estimated $255.
  • Tradewinds Capital Management first reported a position in Cardiol Therapeutics in Q3 2021 and held it in 6 quarters.
  • Tradewinds Capital Management's Cardiol Therapeutics position peaked at $2K in Q3 2021.
  • 35 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2023.

Based on Tradewinds Capital Management's 13F filing for Q1 2023, filed 10 Apr 2023.